Five notes:
1. Quarterly revenue increased 5.3% year over year. The company’s cardiovascular portfolio saw 6.1% growth year over year with $3.1 billion, and its medical surgical portfolio grew 1.2% year over year with $2.1 billion.
2. Medtronic’s neuroscience portfolio saw a 7.1% increase in revenue year over year with $2.5 billion.
3. Cranial and spinal technology sales were $1.2 billion, a 6.7% increase year over year. Specialty therapies grew 4.6% with $737 million in sales.
4. Neuromodulation sales saw significant gains with $480 million, a 12.6% increase year over year.
5. Medtronic saw $1.3 billion in net income. The company is also raising its full-year guidance for fiscal year 2025 to 4.75% to 5% growth year over year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
